Development of a new tri-block copolymer with a functional end and its feasibility for treatment of metastatic breast cancer

  • Ho Taek Song
  • , Ngoc Ha Hoang
  • , Jeong Min Yun
  • , Young Jin Park
  • , Eun Hye Song
  • , Eun Seong Lee
  • , Yu Seok Youn
  • , Kyung Taek Oh

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

We have developed nanomedicine vehicle based on a biocompatible tri-block copolymer, poly(ethylene glycol)-block-poly(lactic acid)-block-poly(ethylene glycol) (PEG-PLA-PEG) by simple approach without toxic linker to escalate therapeutic efficacy of anticancer agent by enhanced targeting to metastasized breast cancers. The synthesized ABA type copolymer had a low polydispersity index and formed small, highly stable spherical micelles. Furthermore, a functional group at the end site of the copolymer can be decorated with imaging agents and targeting moieties. The doxorubicin loaded micelles (DLM) showed higher drug-loading capacity, faster drug release, and better cell toxicity compared to those using di-block copolymers. DLM efficiently delivered to the metastatic breast cancers in brain and bone and suppressed growing of metastasis. In demonstration of treating metastasized animal model, we present a tri-block copolymer as a potential nanomedicine vehicle to efficiently deliver anticancer drug and to effectively treat metastatic breast cancer.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalColloids and Surfaces B: Biointerfaces
Volume144
DOIs
StatePublished - 1 Aug 2016

Bibliographical note

Publisher Copyright:
© 2016.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Animal imaging
  • Biocompatibility
  • Metastasis
  • Nanomedicine
  • Tri-block copolymer

Fingerprint

Dive into the research topics of 'Development of a new tri-block copolymer with a functional end and its feasibility for treatment of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this